Epicutis announced the launch of Hydrobiome Serum, a product as a professional skin care treatment built around the patented TCP molecule.
The company reports a double-blind and placebo-controlled study conducted by Princeton Consumer Research (N = 48, 8 weeks), in which the subjects using the TCP formula showed a 77% improvement in the overall appearance of the skin from the initial level compared to 56% in the comparison group, and showed a measurable improvement in vehicle control, and the company stated that the TCP company did not experience discomfort, dryness or discomfort.
According to the company, Hydrobiome Serum pairs TCP with sodium tocopheryl phosphate (TPNa) and is designed to modulate membrane lipid signaling to support barrier integrity, hydration balance and reduce visible redness without suppressing extensive immune activity.
Products are available only through licensed estheticians, dermatology practices and accredited med-spa partners, consistent with Epicutis’ professional channel strategy.
The technology is associated with Signum Biosciences’ patented isoprenyl cysteine compound, and all claims refer to Princeton Consumer Research clinical data on file.
